What are the possible causes of hypoglycemia in a woman with metastatic breast cancer receiving levothyroxine for hypothyroidism?

Possible Diagnoses for Hypoglycemia in a Woman with Metastatic Breast Cancer on Levothyroxine

In this patient with metastatic breast cancer and hypothyroidism on levothyroxine, the most likely diagnoses are non-islet cell tumor hypoglycemia (NICTH) from her malignancy, medication-related hypoglycemia (particularly levothyroxine in the setting of potential hepatic metastases), critical illness from advanced cancer, or less likely, adrenal insufficiency or accidental/surreptitious drug exposure.

Primary Diagnostic Considerations

1. Non-Islet Cell Tumor Hypoglycemia (NICTH)

This is the most critical diagnosis to consider given her metastatic breast cancer 1. NICTH typically occurs with:

• Large, clinically apparent tumors (often mesenchymal, but can occur with other malignancies)
• Overproduction of incompletely processed IGF-II (pro-IGF-II)
• Suppressed endogenous insulin secretion (insulin <3 µU/mL, C-peptide <0.6 ng/mL)
• Elevated IGF-II to IGF-I ratio due to suppressed growth hormone
• Can occur with metastatic leiomyosarcoma and other tumors 2

Key distinguishing features: The hypoglycemia is mediated by IGF, NOT insulin, so insulin and C-peptide will be appropriately suppressed 1.

2. Levothyroxine-Associated Hypoglycemia with Hepatic Impairment

This is particularly relevant if she has liver metastases 3. The risk is:

• Dramatically increased in patients with liver impairment (adjusted OR 14.68 in those with liver impairment vs. 4.50 with normal liver function)
• Risk elevation depends on lowering of liver reserve
• Mechanism unclear but clinically significant 3

3. Critical Illness-Related Hypoglycemia

Advanced metastatic cancer constitutes a critical illness that can cause hypoglycemia through 1:

• Hepatic failure (if liver metastases present)
• Severe malnutrition/cachexia
• Sepsis (if concurrent infection)

4. Adrenal Insufficiency

While less common, this must be considered 1:

• Can occur with metastatic disease
• Important caveat: A low cortisol during spontaneous hypoglycemia is NOT sufficient for diagnosis, as recurrent hypoglycemia shifts glycemic thresholds for cortisol secretion lower 1
• Requires formal adrenal testing when not hypoglycemic

5. Medication-Related Causes

Beyond levothyroxine, consider 1:

• Accidental or surreptitious use of insulin or sulfonylureas (pharmacy errors do occur) 1
• Alcohol (if patient consuming alcohol, which inhibits gluconeogenesis) 4
• Other medications she may be receiving for cancer or supportive care

6. Less Likely but Possible

• Insulinoma or endogenous hyperinsulinism: Would show elevated insulin (≥3 µU/mL), C-peptide (≥0.6 ng/mL), and proinsulin (≥5.0 pmol/L) during hypoglycemia 1
• Post-surgical hypoglycemia: Only if she had prior gastric surgery 1, 4

Recommended Diagnostic Approach

During a documented hypoglycemic episode (glucose <55 mg/dL), immediately measure 1:

• Plasma glucose, insulin, C-peptide, proinsulin
• β-hydroxybutyrate
• Screen for oral hypoglycemic agents
• Insulin antibodies
• Administer 1.0 mg glucagon IV and observe glucose response

If insulin/C-peptide are suppressed (insulin <3 µU/mL, C-peptide <0.6 ng/mL):

• Measure IGF-I and IGF-II levels
• Calculate IGF-II to IGF-I ratio (elevated in NICTH) 1
• Assess for pro-IGF-II if available 1
• Evaluate extent of metastatic disease and liver function

If cannot capture spontaneous episode:

• Perform supervised 72-hour fast with serial measurements 1

Additional workup:

• Review ALL medications (including over-the-counter)
• Assess liver function and extent of hepatic metastases
• Consider cortisol stimulation testing if adrenal insufficiency suspected (but NOT during hypoglycemia) 1

Critical Pitfalls to Avoid

1. Do not diagnose adrenal insufficiency based solely on low cortisol during hypoglycemia 1
2. Do not assume insulinoma without documenting elevated insulin/C-peptide during hypoglycemia
3. Do not overlook medication causes—always screen for oral hypoglycemic agents even if patient denies use 1
4. Do not miss NICTH—this is the most likely diagnosis given her metastatic cancer and has significant implications for prognosis and management 1, 2

The diagnosis hinges on biochemical documentation during hypoglycemia, with NICTH being the leading consideration given her metastatic breast cancer, followed by levothyroxine-related hypoglycemia if hepatic metastases are present 1, 3.